Health
Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Ach
About this update from Achieve Life Sciences, Inc.
[{"type":"image","alt":"Achieve Life Sciences","displaySize":"","headline":null,"caption":"Achieve Life Sciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/54cb79df5ae9ba9fc58a8a917402fc80"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UhVN6FI.pSC2XZoJQyyabQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/54cb79df5ae9ba9fc58a8a917402fc80","width":300,"height":157}},"lazy":false},{"type":"text","content":"Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone","length":123,"tagName":"p"},{"type":"text","content":"If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for nicotine dependence in two decades","length":123,"tagName":"p"},{"type":"text","content":"More than 2,000 clinical trial participants contributed to the body of evidence submitted in the NDA demonstrating cytisinicline’s efficacy, safety, and tolerability profile ","length":173,"tagName":"p"},{"type":"text","content":"SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for cytisinicline as a treatment of nicotine dependence for smoking cessation in adults.","length":478,"tagName":"p"},{"type":"text","content":"“Submitting the cytisinicline NDA represents a decade of research and is a significant milestone toward delivering a new, evidence-based potential treatment for nicotine dependence, an urgent public health challenge with few effective options,” stated Dr. Cindy Jacobs, President and Chief Medical Officer of Achieve Life Sciences. “Smoking-related illnesses claim the lives of nearly half a million people annually in the U.S. alone, and we are committed to making an impact. We look forward to collaborating closely with the FDA during the review process and remain hopeful about the potential of cytisinicline to make a meaningful difference for patients and healthcare providers who are seeking new treatment o...